Launches include the first commercially available singleplex eMTBR-Tau immunoassay, a novel pTau 217 assay for venous and capillary blood, and a fully automated instrument platform
Explore the role of alpha synuclein biomarkers in supporting the detection and monitoring of Parkinson’s disease
SPEAR overcomes immunoassay complexity and sensitivity limitations in Alzheimer’s and neurodegenerative biomarker research with a homogeneous, wash-free format
Yao Chen of Sanofi shares how her team achieves sensitivity, specificity, precision, and robustness in protein biomarker detection
Advancing early Alzheimer's diagnosis with scalable, ultra-sensitive technology
